Aclarion Inc., a Broomfield health care technology company, has reported that UHealth — University of Miami Health System and the University of Miami Miller School of Medicine will be a site for its CLARITY clinical trial. This trial aims to evaluate the effectiveness of Nociscan, a solution designed to assist physicians in identifying sources of...
Highridge Medical has completed the sale of its Bone Healing division to Avista Healthcare Partners. This move aims to help the company focus exclusively on its Spine business and enhance long-term growth through increased investment in innovation and commercial capabilities. The sale proceeds will be directed towards portfolio innovation and expanding the company’s commercial reach....
Aclarion Inc. (Nasdaq: ACON, ACONW) has reported that the Keck Medical Center of USC has joined the CLARITY (Chronic Low Back Pain Randomized Independent Trial Study) as a trial site. The USC Spine Center specializes in treating complex spine conditions using advanced technologies. The CLARITY trial is a randomized clinical study aimed at demonstrating the...
Terumo BCT has reported that Join Parachute will implement the Rika Plasma Donation System, designed to enhance the plasma donation experience and increase donor comfort. This next-generation plasma collection system aims to improve access to lifesaving therapies by rethinking the donation process. Join Parachute is focused on providing greater access to plasma through a donor-first...
Aclarion Inc. (Nasdaq: ACON, ACONW) has reported that the Texas Back Institute (TBI) will serve as a new site for the CLARITY (C hronic L ow b A ck pain R andomized I ndependent T rial stud Y) clinical trial. TBI is widely recognized for its contributions to spine technology, education and patient care. The...
Aclarion Inc. (Nasdaq: ACON, ACONW), a Broomfield health care technology company, has reported that Advocate Aurora Research Institute, part of Advocate Health, will participate as a site in the CLARITY (Chronic Low Back pain Randomized Independent Trial studY) trial. The trial aims to demonstrate the clinical and economic value of Nociscan in spine surgery. “Advocate...
Aclarion Inc. (Nasdaq: ACON, ACONW), a health care technology company based in Broomfield, has established a commercial agreement with the Spine Institute of Louisiana (SIL) in Shreveport, La., expanding access to its Nociscan solution. This collaboration allows SIL, a center known for its innovative treatment of chronic low back pain, to use Nociscan as part...
Aclarion Inc. (Nasdaq: ACON, ACONW) has published a peer-reviewed article in Clinicoeconomics and Outcomes Research, titled “The Comparison of Cost-Effectiveness Between Magnetic Resonance Spectroscopy and Provocative Discography in the Identification of Chronic Low Back Pain Surgery Candidates.” The independent cost-effectiveness analysis concludes that Nociscan is effective and less costly compared to provocative discography. The findings...
Terumo Blood and Cell Technologies (Terumo BCT) named Patrick Daly as its chief business officer. This addition comes as the Lakewood company aims to expand its capabilities in response to evolving market segments. Daly brings over 30 years of experience in the business and health care sectors, having worked both domestically and internationally. He most...
Aclarion Inc. (Nasdaq: ACON, ACONW) reported that its Nociscan product is now available at the Medical Imaging Center of Southern California (MICSC) in Santa Monica. Previously, MICSC offered Nociscan exclusively at its Beverly Hills location. “We are pleased to expand access to Nociscan in our Santa Monica location,” said Dr. Bradley Jabour, founder of MICSC....
Aclarion Inc. (Nasdaq: ACON, ACONW), the Broomfield healthcare technology company focused on chronic low back pain, announced an update on its improved positioning following successful strategic initiatives in the first quarter of 2025. The company raised over $20 million in Q1, maintaining nearly $15 million in cash on hand. Aclarion reported a clean capital structure,...
Aclarion Inc. (NASDAQ: ACON, ACONW) announced a 1-for-27 reverse stock split of its common stock, effective before market open on March 28. On Sept. 23, 2024, the Broomfield-based company’s stockholders approved an amendment to the company’s Certificate of Incorporation to authorize a reverse stock split with the ratio set by its Board of Directors. The...